Australian expressed RNAi drug developer Benitec this week provided an update to its pipeline, disclosing that it once again expects to have a candidate in phase I testing next year following its recent acquisition of Tacere Therapeutics.
The rest of the firm's pipeline, however, remains unlikely to reach human testing until at least 2014 — in line with amended guidance provided during the summer.
Also this week, the company released its financial results for the fiscal year ended June 30, posting higher losses on increased spending.